Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial

Manuscript Number: 

21-0570R2

Author(s): 
Jeffrey Cummings, Henry N. Ginsberg, Chris Halliday, Jan O. Johansson, Kamyar Kalantar-Zadeh, Aziz Khan, Ewelina Kulikowski, Kenneth Lebioda, Stephen J. Nicholls, Kausik K. Ray, Gregory G. Schwartz, Michael Sweeney, Peter P. Toh, Bengt Winblad, Norman C.W. Wong, Henrik Zetterberg

Disclosures

Jeffrey Cummings

  • Consulting Fees:
    JC has provided consultation to Acadia, Alkahest, AriBio, Avanir, Axsome, Behren Therapeutics, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Jazz, Karuna, LSP, Merck, Novo Nordisk, Otsuka, ReMYND, Resverlogix, Roche, Signant Health, Sunovion, Suven, United Neuroscience, and Unlearn AI pharmaceutical and assessment companies.
    Equity:
    JC has stock options in ADAMAS, Acumen, Alkahest, Alzheon, AnnovisBio, MedAvante, BiOasis, and United Neuroscience.
    Patents/Royalties
    JC owns the copyright of the Neuropsychiatric Inventory (NPI) and receives royalties.

Henry N. Ginsberg

  • Consulting Fees:
    Reverlogix consultant 1-2 times per year :$1000

Chris Halliday

  • Equity:
    Resverlogix Corp. shareholder

Jan O. Johansson

  • Equity:
    Employ of company with incentives in form of stock options
    Sponsors:
    Employed as senior vice president medical affairs

Kamyar Kalantar-Zadeh

  • Consulting Fees:
    Resverlogix 9Steering Committee)

Aziz Khan

  • Equity:
    Aziz Khan owns RSUs in Resverlogix Corp.
    Sponsors:
    Aziz Khan is a full-time employee of Resverlogix Corp., with the title of "Manager of Business and Corporate Data Analysis".

Ewelina Kulikowski

  • Equity:
    stock options
    Sponsors:
    employee

Kenneth Lebioda

  • Equity:
    Equity in RVX Stock Shares

Stephen J. Nicholls

  • Consulting Fees:
    AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim
    Grants
    • Agency: 
      AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience
      Dates: 
      Current

Kausik K. Ray

  • Consulting Fees:
    Resverlogix, Amgen, Novartis, Sanofi, Abbott, Novo Nordisk, Boehringer Ingelheim, Kowa, Regeneron, Astra Zeneca, Pfizer, Silence Therapeutics, Daiichi Sankyo, Esperion, Bayer
    Lecture Fees:
    Amgen, Novartis, Sanofi, Viatris, Novo Nordisk, Boehringer Ingelheim, Astra Zeneca, Daiichi Sankyo
    Grants
    • Agency: 
      Amgen
      Dates: 
      2020 and ongoing
    • Agency: 
      Regeneron
      Dates: 
      2021 and ongoing
    • Agency: 
      Daiichi Sankyo
      Dates: 
      2020 and ongoing
    • Agency: 
      Sanofi
      Dates: 
      2016 and ongoing

Gregory G. Schwartz

  • Grants
    • Agency: 
      Resverlogix Corp
      Dates: 
      2015-2021
    • Agency: 
      Sanofi
      Dates: 
      2011-2021
    • Agency: 
      The Medicines Company
      Dates: 
      2015-2021
    • Agency: 
      AstraZeneca
      Dates: 
      2020-2021

Michael Sweeney

  • Equity:
    Stock in Resverlogix
    Sponsors:
    Resverlogix employee

Peter P. Toh

  • Consulting Fees:
    I am a consultant to Amarin, AstraZeneca, bio89, Kowa, Merck, Resverlogix, and Theravance.
    Lecture Fees:
    Amarin, Amgen, Esperion, Merck, Novo-Nordisk
    Patents/Royalties
    Expert witness for Amarin

Bengt Winblad

  • Lecture Fees:
    Scientific Advisory Board meeting for Alzhemed, Axon pharma, Alzecure, Biogen

Norman C.W. Wong

  • Equity:
    Options of less than 0.5%

Henrik Zetterberg

  • Consulting Fees:
    HZ has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs. Payments made to HZ.
    Equity:
    HZ is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work), and holds stock in the company.
    Lecture Fees:
    HZ has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen. Payments made to HZ.